Showing results (301-310 of 793) with videos related to
Sort By:
Pageof 80
The Journal of Applied Laboratory Medicine|May 26, 2023
Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined SignificanceKrasimira Rozenova, Maria Willrich, Melissa Snyder, et al.Blood Cancer Journal|July 30, 2020
In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myelomaAmit Kumar Mitra, Harish Kumar, Vijay Ramakrishnan, et al.Clinical Advances in Hematology & Oncology : H&O|October 7, 2022
Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directionsDunya Alsomali, Dania Mohty, Martha Grogan, et al.Clinical Lymphoma, Myeloma & Leukemia|June 27, 2025
Monoclonal Gammopathies in AfricaAbiola Bolarinwa, Lateef Odukoya, Francis Buadi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.Cancer|April 27, 2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomasRajni Sinha, Jonathan L Kaufman, Hanna Jean Khoury, et al.Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple MyelomaYael C Cohen, Albert Oriol, Ka Lung Wu, et al.Transfusion|April 16, 2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kineticsJie Li, Ellie Hamilton, Louette Vaughn, et al.Pageof 80